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INTRODUCTION
The current diagnostic method of surgically resected thy-
roid nodules is pathologic evaluation of routine hematoxylin
and eosin stained slides. For example, the diagnosis of pap-
illary thyroid carcinoma is based on the presence of papillary
architecture and characteristic nuclear features, such as ground
glass nuclei, nuclear pseudoinclusions, and nuclear grooves
(1). In cases of follicular variant of papillary carcinoma, the
pathologic diagnosis depends on the typical nuclear changes
of papillary thyroid carcinoma. However, the interpretation
of nuclear features may be quite subjective and interobserver
disagreements among pathologists are well documented (2,
3). The diagnosis of encapsulated follicular lesions is also quite
problematic, especially when minor nuclear changes seen in
typical papillary carcinoma are found (3). However, an accu-
rate diagnosis is crucial for the appropriate treatment and
long-term management of tumors, and thus many immuno-
histochemical markers have been suggested to aid in the dif-
ferential diagnosis of thyroid nodules. 
Galectin-3 is a member of a growing family of  -galacto-
side-binding animal lectins, involved in the regulation of
cell-cell and cell-matrix interaction, cell growth, neoplastic
transformation, and apoptosis (4). Many studies have found
that galectin-3 expression is of value in discriminating benign
and malignant thyroid nodules (5-13), although a few reports
contradict the results (14, 15). Generally, it has been suggested
as a marker of thyroid malignancy with relatively high sensi-
tivity and specificity, especially in papillary carcinoma (5-13).
HBME-1 is a monoclonal antibody generated against an
unknown membrane antigen of mesothelial cells (16). It was
also reported to show preferential reactivity with malignant
thyroid tumors (11, 12, 17-19).
The differential expression of cytokeratins has been evalu-
ated in various thyroid lesions. Among various cytokeratins,
cytokeratin 19 (CK19) has been reported to be useful in the
diagnosis of papillary carcinoma, where it has shown diffuse
and strong cytoplasmic staining (11-13, 20-22). The expres-
sion of high molecular weight cytokeratin (HMWCK), al-
though patchy, has also been found to be significantly increased
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Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High 
Molecular Weight Cytokeratin, Cyclin D1 and p27
kip1 in the Differential
Diagnosis of Thyroid Nodules
The distinction between benign and malignant thyroid tumors is critical for the man-
agement of patients with thyroid nodules. We applied immunohistochemical stain-
ing for galectin-3, HBME-1, cytokeratin 19 (CK19), high molecular weight cytoker-
atin (HMWCK), cyclin D1 and p27
kip1 in 295 thyroid lesions to determine their diag-
nostic accuracy. The expression of all markers was significantly associated with
differentiated thyroid carcinoma (DTC).The sensitivity for the diagnosis of DTC was
94.7% with galectin-3, 91.3% with HBME-1, and 90.3% with CK19. The specifici-
ties of these markers were 95.5%, 69.7%, and 83.1%, respectively. Combining
these markers, co-expression of galectin-3 and CK19 or galectin-3 and HBME-1
was seen in 93.2% of carcinomas but in none of the benign nodules. Comparing
follicular variant of papillary carcinoma (FVPC) with follicular carcinoma (FC), the
expression of galectin-3, CK19, and HMWCK was significantly higher in FVPC.
When comparing FC with FA, the expression of galectin-3 and HBME-1 was signifi-
cantly higher in FC. These results suggest that 1) galectin-3 is a useful marker in
the distinction between benign and malignant thyroid tumors, 2) the combined use
of HBME-1 and CK19 can increase the diagnostic accuracy, and 3) the use of CK19
and HMWCK can aid in the differential diagnosis between PC and FC.
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in papillary thyroid carcinoma and has been reported to be
helpful in distinguishing it from other benign and malignant
thyroid nodules (20, 23).
The loss of regulatory control of the cell cycle, leading to
unrestrained cell proliferation, is a hallmark of cancers. Cyclin
D1 plays a key role in the regulation of the G1/S transition
through the cell cycle. Although little is known about the
role of cyclin D1 in the pathogenesis of thyroid carcinoma,
its overexpression has been reported in malignant thyroid
tumors (24-26). p27kip1, a cyclin-dependent kinase inhibito-
ry protein, is down-regulated in thyroid carcinoma and report-
ed to be useful in the differential diagnosis of papillary hyper-
plasia in Grave’s disease and papillary thyroid carcinoma (25,
27-29).
Most studies have evaluated the single expression of mark-
ers in various thyroid lesions and a few reports have studied
the combined expression of markers (11, 12, 18). In this study,
we compared the single or combined expression of galectin-
3, HBME-1, CK19, HMWCK, cyclin D1 and p27kip1 in a
large number of benign and malignant thyroid lesions to
determine their diagnostic accuracy in the differential diag-
nosis of thyroid nodules.
MATERIALS AND METHODS
Tissue specimens
Two hundred forty-one consecutive cases of thyroid tumors
including 181 papillary carcinomas, 25 follicular carcinomas,
and 35 follicular adenomas were collected from Seoul Nation-
al University Bundang Hospital from May 2003 to April
2005. The papillary carcinomas included 76 classic, 17 fol-
licular and 4 tall cell variants, and 84 microcarcinomas. The
follicular carcinoma cases included 3 metastatic follicular car-
cinomas in the lung or vertebra, 2 widely invasive follicular
carcinomas, and 20 minimally invasive follicular carcinomas.
Minimally invasive follicular carcinomas were diagnosed by
the presence of definite capsular and/or vascular invasion. We
also included 54 nodular hyperplasias to study the expres-
sion of markers in non-neoplastic thyroid nodules. All cases
were reviewed and confirmed by an endocrine pathologist. 
Immunohistochemistry and interpretation
All specimens were fixed in 10% buffered formalin, embed-
ded in paraffin wax, and stained with hematoxylin and eosin
(H-E) for histologic examination. Representative paraffin
blocks selected for immunohistochemistry included both
the tumor and the normal thyroid tissue. 
Four micron-thick sections were deparaffinized, rehydrat-
ed in graded alcohols, and processed using DAKO envision
detection kit (DakoCytomation, Carpinteria, CA, U.S.A.).
Briefly, antigen retrieval was performed in a microwave oven
for 15 min in 10 mM citrate buffer pH 6.0. Endogenous
peroxidase activity was blocked with a 3% H2O2-methanol
solution, and the slides were incubated in 10% normal goat
serum for 30 min to prevent non-specific staining. They were
then incubated for 1 hr at room temperature with an appro-
priately diluted primary antibody. The following mouse mon-
oclonal antibodies were used: galectin-3 (clone 9C4; 1:600;
Novocastra, Newcastle, U.K.), HBME-1 (clone HBME-1;
1:100; DakoCytomation, Carpinteria, CA, U.S.A.), CK19
(clone RCK108; 1:150; DakoCytomation), HMWCK (clone
34 E12; 1:150; DakoCytomation), cyclin D1 (clone SP4;
1:100; Labvision, Fremont, CA, U.S.A.), p27kip1 (clone SX-
53G8; 1:200; DakoCytomation). Thereafter, the sections
were incubated with DAKO Envision/HRP for 30 min. Dia-
minobenzidine was used as a chromogen, and the sections
were counterstained with Mayer’s hematoxylin. As a nega-
tive control, non-immune serum was substituted for the
primary antibody. 
Galectin-3 expression was both cytoplasmic and/or nuclear.
HBME-1 was expressed in the cytoplasm and cell membrane
with occasional luminal accentuation. CK19 and HMWCK
expressions were cytoplasmic with membranous accentuation.
Cyclin D1 and p27kip1 were mostly expressed in the nucleus
with occasional cytoplasmic staining and only nuclear stain-
ing was counted. 
The expression of markers except for p27kip1 was assessed
as follows: 0, no staining or staining in less than 10% of the
tumor cells; 1+, staining in 10% to 25% of the cells; 2+,
staining in 26% to 50% of the cells; 3+, staining in 51% to
75% of the cells; 4+, staining in more than 75% of the cells.
Staining of 1+or 2+was defined as focal staining, and stain-
ing of 3+ or more was defined as diffuse staining. For statis-
tical analysis, cases with any degree of positive staining were
grouped as positive. For p27kip1, no staining or staining in less
than 10% of the tumor cells were defined as loss of p27kip1.
Statistical analysis
Statistical analysis was performed with SPSS software (ver-
sion 11.0, SPSS Inc., Chicago, IL, U.S.A.). Chi-square or Fish-
er’s exact tests were used when comparing frequencies bet-
ween groups. The sensitivity, specificity, and accuracy of the
markers and their combination in the diagnosis of differen-
tiated thyroid carcinomas (DTC) including both papillary
and follicular carcinomas were compared. Probability values
less than 0.05 were considered statistically significant.
RESULTS
Expression of markers and their diagnostic value in DTC
The expression of galectin-3, HBME-1, CK19, HMWCK,
cyclin D1, and p27kip1 in various thyroid nodules is shown inTable 1. The overexpression of all markers except p27kip1 and
the loss of p27kip1 were significantly associated with DTC (p<
0.001 in all markers). 
The sensitivity, specificity, and diagnostic accuracy of the
markers for the diagnosis of DTC are summarized in Table
2. Galectin-3, HBME-1, and CK19 expressions were highly
sensitive, but HMWCK and cyclin D1 expression and loss
of p27kip1 showed intermediate or low sensitivity. The expres-
sion of galectin-3 or HMWCK was highly specific for DTC.
The expression of galectin-3 in the benign nodule was only
4.5% (4/89) and HMWCK was not detected in any of the
89 benign nodules.
From these results, we concluded that galectin-3 is the
most useful marker for the detection of DTC, and we sub-
analyzed the individual cases showing false-positive or false-
negative staining for galectin-3. 
Four benign nodules showed galectin-3 expression, one
case being follicular adenoma and three cases being nodular
hyperplasia. Two cases of nodular hyperplasia exhibited benign
papillary hyperplasia. All the cases showed focal and weak
staining for galectin-3, and there was no expression of HBME-
1 or CK19 (Fig. 1). 
On the contrary, 11 malignant tumors were negative for
galectin-3. One case was a follicular variant of papillary car-
cinoma, another was a papillary microcarcinoma with follic-
ular pattern and the others were follicular carcinomas. One
of the galectin-3-negative follicular carcinomas was a meta-
static tumor in the spine. All these cases showed positive
staining for HBME-1, and eight of the cases were positive
for CK19.
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Diagnosis
Pattern of expression
n Galectin-3 HBME-1 CK19 HMWCK Cyclin D1 p27
kip1 loss*
DTC (total) 206 195 (94.7%)
� 188 (91.3%)
� 186 (90.3%)
� 108 (52.4%)
� 131 (63.6%)
� 166 (80.6%)
�
Papillary carcinoma 181 179 (98.9%)
� 166 (91.7%) 175 (96.7%)
� 108 (59.7%)
� 121 (66.9%)
� 151 (83.4%)
�
Diffuse:focal 170:9 129:37 162:13 32:76 28:93
Follicular carcinoma 25 16 (64.0%)
� ,� 22 (88.0%)
‖ 11 (44.0%)
� 0 (0%)
� 10 (40.0%)
� 15 (60.0%)
�
Diffuse:focal 7:9 16:6 6:5 0:0 3:7
Benign thyroid nodule (total) 89 4 (4.5%)
� 28 (31.5%)
� 15 (16.9%)
� 0 (0%)
� 13 (14.6%)
� 19 (21.3%)
�
Follicular adenoma 35 1 (2.9%)
� 17 (48.6%)
‖ 10 (28.6%) 0 (0%) 12 (34.3%) 14 (40.0%)
Diffuse:focal 0:1 11:6 4:6 0:0 1:11
Nodular hyperplasia 54 3 (5.6%) 11 (20.4%) 5 (9.3%) 0 (0%) 1 (1.9%) 5 (9.3%)
Diffuse:focal 0:3 1:10 0:5 0:0 0:1
Table 1. Expression of the markers in differentiated thyroid carcinoma (DTC) and benign thyroid nodule
*The pattern of expression is not applicable in p27
kip1 loss; 
�
p<0.001, DTC vs. benign thyroid nodule; 
�
p<0.001, papillary carcinoma vs. follicular carci-
noma; 
�
p<0.001; 
‖p=0.0017, follicular carcinoma vs. follicular adenoma.
CK19, cytokeratin; HMWCK, high molecular weight cytokeratin.
Fig. 1. Benign papillary hyperplasia in nodular hyperplasia showing focal expression of galectin-3 (A) and no expression of HBME-1 (B).
A B624 Y.J. Park, S.H. Kwak, D.C. Kim, et al.
Combined expression of markers and their diagnostic
value in DTC 
To improve the diagnostic accuracy of galectin-3, we ana-
lyzed the combined effect of other sensitive markers, HBME-
1 or CK19 (Table 2). The expression of galectin-3 or HBME-
1 was noted in 100% of carcinomas and 34.8% of benign
nodules (p<0.001). The expression of galectin-3 or CK19
was detected 98.5% of carcinomas and 21.3% of benign nod-
ules (p<0.001). When we analyzed the co-expression of galec-
tin-3 and HBME-1 or galectin-3 and CK19, the specificity
was improved up to 100%, but the sensitivity was not higher
than that of galectin-3 alone.
Differences in the expression of markers between 
papillary and follicular carcinoma 
When comparing papillary carcinoma and follicular car-
cinoma, the expression of galectin-3, CK19, HMWCK, cyclin
D1 and the loss of p27kip1 was significantly higher in papil-
lary carcinoma than in follicular carcinoma (p<0.001; Table
1, Fig. 2). HBME-1 was highly expressed in both papillary
and follicular carcinoma (91.7% and 88.0%, respectively).
When comparing follicular variant of papillary carcinoma
with follicular carcinoma, the expression of galectin-3 (p=
0.031), CK19 (p<0.001) and HMWCK (p=0.002) were sig-
nificantly higher in follicular variant of papillary carcinoma
than in follicular carcinoma (Table 3). The expression of HB-
ME-1 and cyclin D1 and the loss of p27kip1 were not signifi-
cantly different between the two groups. 
Differences in the expression of markers among variants
of papillary carcinoma
We also evaluated the differences in immunohistochemical
findings in the variants of papillary carcinoma. When com-
paring follicular variant of papillary carcinoma with classic
papillary carcinoma, the expression of HMWCK (p=0.008)
was significantly lower in follicular variant of papillary car-
cinoma than in classic papillary carcinoma (Table 3). No sig-
nificant differences were found between follicular variant of
papillary carcinoma and classic papillary carcinoma for the
expression of other markers except for HMWCK.
Differences in the expression of markers between follicular
carcinoma and follicular adenoma
The expression of galectin-3 and HBME-1 was significantly
higher in follicular carcinomas than in follicular adenomas
(Table 1, Fig. 3). Galectin-3 was detected in 64.0% of follic-
ular carcinomas and 2.9% of follicular adenomas (p<0.001).
HBME-1 was expressed in 88% of follicular carcinomas and
48.6% of follicular adenomas (p=0.0017). The expression of
CK19, HMWCK, cyclin D1 and p27 were not significantly
different between follicular carcinoma and adenoma (Table
1). CK19 was expressed in 44.0% of follicular carcinomas
*p=0.031; 
� p<0.001; 
� p=0.002, follicular carcinoma vs. follicular variant
of papillary carcinoma; 
�p=0.008, follicular variant of papillary carcino-
ma vs. classic papillary carcinoma.
CK19, cytokeratin 19; HMWCK, high molecular weight cytokeratin.
Expression of 
markers
Follicular 
carcinoma 
(n=25)
Follicular
variant of
papillary 
carcinoma
(n=17)
Classic 
papillary 
carcinoma
(n=76)
Galectin-3 16 (64.0%)* 16 (94.1%)* 76 (100%)
HBME-1 22 (88.0%) 16 (94.1%) 69 (90.8%)
CK19 11 (44.0%)
� 17 (100%)
� 74 (97.4%)
HMWCK 0 (0%)
� 6 (35.3%)
� ,� 53 (69.7%)
�
Cyclin D1 10 (40.0%) 9 (52.9%) 57 (75.0%)
P27
kip1 loss 15 (60.0%) 13 (76.5%) 61 (80.3%)
Table 3. Expression of immunohistochemical markers in follicu-
lar carcinoma, follicular variant of papillary carcinoma, and clas-
sic papillary carcinoma
Expression of marker Sensitivity Specificity PPV NPV Accuracy
Galectin-3 (+) 94.7% 95.5% 98.0% 88.5% 94.9%
HBME-1 (+) 91.3% 68.5% 87.0% 77.2% 84.4%
CK19 (+)  90.3% 83.1% 92.5% 78.7% 88.1%
HMWCK (+) 52.4% 100% 100% 47.6% 66.8%
Cyclin D1 (+) 63.6% 85.4% 91.0% 50.3% 70.2%
P27
kip1 loss 80.6% 78.7% 89.7% 63.6% 80.0%
Galectin-3 (+) or HBME-1 (+) 100% 65.2% 86.9% 100% 89.5%
Galectin-3 (+) or CK19 (+) 98.5% 78.7% 91.4% 95.9% 92.5%
Galectin-3 (+) & HBME-1 (+) 85.9% 100% 100% 75.4% 90.2%
Galectin-3 (+) & CK19 (+) 86.4% 100% 100% 76.1% 90.5%
Galectin-3 (+) & HBME-1 (+) or  93.2% 100% 100% 86.4% 95.3%
galectin-3 (+) & CK19 (+)
Table 2. Sensitivity, specificity, positive predictive value, negative predictive value, and diagnostic accuracy of the immunohistochemical
markers in the diagnosis of differentiated thyroid carcinoma
PPV, positive predictive value; NPV, negative predictive value; CK19, cytokeratin 19; HMWCK, high molecular weight cytokeratin.Diagnostic Markers of Thyroid Carcinoma 625
and 28.6% of follicular adenomas.
DISCUSSION
In this study, we evaluated the diagnostic accuracy of galec-
tin-3, HBME-1, CK19, HMWCK, cyclin D1, and p27kip1
in the differential diagnosis of thyroid nodules. We found
that galectin-3, HBME-1, and CK19 were highly sensitive
for DTC, but galectin-3 was the most sensitive and specific. 
Galectin-3 has been suggested to be a highly sensitive and
reliable diagnostic marker for the preoperative identification
of thyroid carcinomas (5, 6, 8). In a large multicenter study
by Bartolazzi et al. (8), the sensitivity and the specificity of
galectin-3 immunodetection in the differential diagnosis of
benign and malignant thyroid lesions were higher than 99%
and 98%, respectively. Although galectin-3 has been consis-
tently suggested to be a very sensitive marker for papillary
carcinoma (5-13), some studies revealed that it shows low
reactivity in follicular carcinoma (7, 9, 12). Our study also
showed that the expression of galectin-3 was significantly
higher in papillary carcinomas than in follicular carcinomas
(98.9% vs. 64.0%; p<0.001). In addition, whereas most of
the papillary carcinomas showed diffuse and strong positivi-
ty to galectin-3, follicular carcinomas showed focal positivi-
ty in 9 (56%) of 16 galectin-3 positive cases, especially in
Fig. 2. Papillary carcinoma showing diffuse expression of galectin-3 (A), HBME-1 (B), CK19 (C), and cyclin D1 (D).
A B
C Dthe subcapsular area. Thus, the use of galectin-3 immuno-
histochemistry in aspiration cytology samples may result in
erroneously negative results.
Some recent studies also demonstrated that galectin-3 is
highly expressed in benign thyroid lesions and in normal
thyroid tissue (11, 14, 15). The discrepancies in the frequen-
cy of galectin-3 immunoreactivity in benign lesions may be
related to the different antibody detection systems and the
cut-off values for positive and negative staining. In the thy-
roid gland, endogenous biotin is invariably expressed in thy-
rocytes, mostly in Hurthle cells. Thus, a biotin-based detec-
tion system may provide false positive results. It has been
suggested that galectin-3 immunodetection may be a useful
adjunct in the distinction between benign and malignant
thyroid tumors, only if performed in a biotin-free detection
system (9, 10).
Besides galectin-3, several markers have been investigat-
ed as useful markers for the diagnosis of thyroid carcinoma.
HBME-1 has been reported to be one of the most promis-
ing markers (11, 12, 17-19). HBME-1 seems to be a sensi-
tive marker for thyroid carcinoma, especially in follicular car-
cinoma. In our study, it was expressed in 88% of follicular
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Fig. 3. Expression of galectin-3 and HBME-1 in follicular neoplasm. Follicular carcinoma showing focal expression of galectin-3 (A) and dif-
fuse expression of HBME-1 (B) in area of capsular invasion. Follicular adenoma showing no expression of galectin-3 (C) and focal expres-
sion of HBME-1 (D).
A B
C Dcarcinomas, compared with the 64% positivity for galectin-
3. However, HBME-1 was also expressed in 48.6% of follic-
ular adenomas and 20.4% of nodular hyperplasias, these fre-
quencies being similar or slightly higher than those previ-
ously reported (12, 17, 19). Thus, although HBME-1 con-
tributes to the diagnosis of DTC, it cannot be applied in the
preoperative or differential diagnosis of follicular-patterned
lesions due to its low specificity.
CK19 has been reported to be strongly and diffusely exp-
ressed in papillary carcinoma, whereas it is usually absent or
focally expressed in follicular carcinoma and benign nodules
(11-13, 20). In our cases, almost all papillary carcinomas in-
cluding follicular variants of papillary carcinoma showed strong
and diffuse CK19 immunoreactivity. However, our nodular
hyperplasias, follicular adenomas, and follicular carcinomas
also showed CK19 immunoreactivity in 9.3%, 28.6%, and
44.0% of cases, respectively, and 20% of follicular carcino-
mas and 11% of follicular adenomas showed diffuse staining
for CK19, although the staining was less intense than that
observed in the papillary carcinoma. It is hard to make any
generalizations about the expression of CK19 in follicular
lesions due to the relative paucity of cases studied, as most
of the previous studies on CK19 expression in thyroid nod-
ules have targeted papillary carcinomas, and the extent of
CK19 immunoreactivity in follicular lesions in the previous
studies is quite variable. The CK19 immunoreactivity of
follicular adenoma in our study was higher than that previ-
ously reported. However, Sahoo et al. (22) reported that 25%
of their follicular adenomas showed extensive immunoreac-
tivity for CK19 (2+in 1, 3+in 4 of 20 follicular adenomas),
and Miettinen et al. (21) also reported that 24% of follicular
adenomas and 59% of follicular carcinomas showed CK19
reactivity in >10% of lesions, suggesting that CK19 patterns
are not reliable in the differentiation between papillary car-
cinomas and follicular neoplasms. Thus, although the immu-
noreactivity for CK19 is more frequent and more diffuse in
papillary carcinoma, its immunoreactivity in follicular lesions
may limit its utility as a diagnostic marker. HMWCK expres-
sion was patchy but strong in 59.7% of papillary carcinomas,
and its staining was less frequent in follicular variants of pap-
illary carcinoma, being expressed in 35.3%. HMWCK seems
to be a highly specific marker for papillary carcinoma; how-
ever, its low sensitivity limits its use in diagnosis.
We attempted to identify a combination of markers with
the greatest diagnostic accuracy. Nikiforova et al. (30) report-
ed that follicular carcinoma with PAX-PPAR rearrange-
ment showed immunoreactivity for galectin-3 but not for
HBME-1 and that those with RAS mutations displayed HB-
ME-1-positive/galectin-3-negative immunophenotype. Thus,
we thought that HBME-1 would complement the low sen-
sitivity of galectin-3 in the diagnosis of follicular carcinoma,
and found that all carcinomas were positive for either galectin-
3 or HBME-1. An immunohistochemical diagnostic panel
comprising these markers increased the sensitivity for DTC
to 100%. However, its specificity for DTC was lowered to
65.2%. When we examined the co-expression of galectin-3
and HBME-1 or galectin-3 and CK19 as a possible marker
of DTC, we found that it was the most specific and accurate
marker with 100% specificity and 95.3% diagnostic accu-
racy. Although this combined use of HBME-1 and CK19
with galectin-3 cannot increase the sensitivity in the diag-
nosis of DTC, it can discriminate galectin-3-positive benign
lesions from galectin-3-positive thyroid carcinomas and thus
increase the specificity.
In our study, the overexpression of cyclin D1 and loss of
p27kip1 were associated with DTC. Their expression was much
higher in papillary carcinomas than in follicular carcinomas,
and there was no difference in expression between follicular
carcinomas and follicular adenomas. There have been a few
reports demonstrating that cyclin D1 and p27kip1 immunos-
taining varies according to tumor phenotype (24-28). How-
ever, in our study, their sensitivity and specificity for DTC
or papillary carcinoma was relatively lower than for the other
markers and thus, were not useful in distinguishing between
benign and malignant thyroid nodules or between papillary
carcinoma and follicular carcinoma. 
In summary, galectin-3 is a useful marker in the distinction
of benign and malignant thyroid tumors, and the combined
use of HBME-1 and CK19 can increase the specificity and
diagnostic accuracy. Galectin-3 and HBME-1 can be used as
adjuncts for the differential diagnosis of follicular neoplasms,
although the low sensitivity of galectin-3 and the low speci-
ficity of HBME-1 for the diagnosis of follicular carcinoma
should be born in mind. In addition, CK19 and HMWCK
can aid in the diagnosis of papillary carcinoma; however, the
low specificity of CK19 and low sensitivity of HMWCK may
limit their utility. 
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